Biotinylated Human TPBG / 5T4 Protein, His, Avitag™

Trophoblast glycoprotein (TPBG), also known as 5T4, is the therapeutic target of several anticancer agents currently in clinical development, largely due to its high expression in tumors and low expression in normal adult tissues.This gene encodes a leucine-rich transmembrane glycoprotein that may be involved in cell adhesion. TPBG is expressed by all types of trophoblasts as early as 9 weeks of development.

Product Specifications

Background

Specifications

This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™) . The protein has a calculated MW of 39.0 kDa. The protein migrates as 50-70 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Accession Number

Q13641-1

Expression Region

Ser 32 - Ser 355

Host

HEK293

Target

TPBG

Conjugation

Biotin-labeled

Tag

C-10xHis & C-Avi

Source

Human

Stability

-20°C to -70°C for 12 months in lyophilized state; -70°C for 3 months under sterile conditions after reconstitution. For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Endotoxin

1.0 EU per μg

Purity

90%

Bioactivity

Immobilized Biotinylated Human TPBG, His,Avitag (Cat. No. TPG-H82Eb) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Anti-TPBG Antibody, Human IgG1 with a linear range of 0.1-4 ng/mL (QC tested).